Age-specific prognostic factors for survival in patients with advanced ovarian cancer (OC) treated with platinum/taxane-based primary chemotherapy: A combined explorative analysis of three prospective phase III trials from the AGO study group.
F. Hilpert
Consultant or Advisory Role - Roche
Honoraria - GlaxoSmithKline; Roche
A. M. Hempel
No relevant relationships to disclose
J. Hedderich
No relevant relationships to disclose
O. Junge
No relevant relationships to disclose
P. Harter
No relevant relationships to disclose
A. Du Bois
Consultant or Advisory Role - Johnson & Johnson; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Roche; Schering-Plough
J. Pfisterer
No relevant relationships to disclose